ResearchMoz

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

GBI Research
Published Date » 2013-10-09
No. Of Pages » N/A
   
 GBI Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). ...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm

3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc
3.1.3 Singulair (montelukast) – Merck & Co
3.1.4 Xolair (omalizumab) – Novartis and Genentech
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance

4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva Pharmaceutical ltd
4.4.2 Mepolizumab - GlaxoSmithKline
4.4.3 Lebrikizumab – Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm Madaus
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Licensing Deals
6.2 Major Co-development Deals

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.2 Market Forecast to 2019
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Pipeline Heat Map
7.3.2 References for Marketed Heat Map
7.4 Market Definitions
7.5 Abbreviations
7.6 Methodology
7.7 Coverage
7.8 Secondary Research
7.9 Therapeutic Landscape
7.10 Epidemiology-Based Forecasting
7.10.1 Analogous Forecasting Methodology
7.11 Market Size by Geography
7.11.1 Forecasting Model for Therapeutic Areas
7.12 Geographical Landscape
7.13 Pipeline Analysis
7.14 Competitive Landscape
7.14.1 Expert Panel Validation
7.15 Contact Us
7.16 Disclaimer

List of Tables


Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths = 12 Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012–2019
Table 14: Asthma, US, Market Forecast, 2012–2019
Table 15: Asthma, Canada, Market Forecast, 2012–2019
Table 16: Asthma, UK, Market Forecast, 2012–2019
Table 17: Asthma, France, Market Forecast, 2012–2019
Table 18: Asthma, Germany, Market Forecast, 2012–2019
Table 19: Asthma, Italy, Market Forecast, 2012–2019
Table 20: Asthma, Spain, Market Forecast, 2012–2019
Table 21: Asthma, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013
Figure 49: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Actuators Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
The mining industry has seen a dramatic change in the use of new sophisticated technologies that has enlarged the scope of mining activities from the onshore locations to the ultra-deep seabed. The mining activities require the use of motors that can be used to control the movements of heavy machineries used in the mining industry. An actuator is a device that is used to produce the mechanical movements by converting the energy from a source into mechanical movements. The sources of energy include the pneumatic pressure, hydraulic fluid pressure or the electric current. The advancements in...
Botanical And Plant Derived Drugs Market - Global Industry Analysis, Size, Share, Growth, Trend And Forecast 2013 - 2019
By - Transparency Market Research
Botanical drugs are drugs develop through botanical drug and research pathway, whereas plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. These botanical products are intended for use in the mitigation, cure, diagnosis and treatment or prevention of diseases in humans.  The global market for botanical and plant derived drugs is witnessing a significant growth over recent years due to rising usage of these drugs in different parts of the world. Increased focus of research...
Fire Alarm Equipments Market - Global Industry Analysis, Size, Share, Trends, Growth And Forecast, 2014 - 2020
By - Transparency Market Research
The market for fire alarm equipments is a mature market on global level, considering the enhanced frequency of accidents and security issues. The fire alarm equipment market has been witnessing a lot of new innovations, for both product and technology. Although the global market for fire alarm equipment market is at a mature stage, the associated products and technologies are still in their growth phase and contribute largely towards the market growth. Moreover, the global market for fire alarm equipments continuously grows with the demand in the construction industry and the mandatory...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Motor Co.s Shares Suffer Downfall as Lower Profit Outlook for 2014-2015 Surface
Oct 1, 2014  
Suffering from higher recall costs in its North American market and great losses in South America and Russia have made Ford motor Co. to cut-down its forecast regarding pretax profit this year to $6 billion from $7 billion to $8 billion as earlier mentioned.  Company’s CFO Bob Shanks said that company’s pretax profit in 2015 is expected to rise between $8.5 and $9.5...
Evereadys Kenya Plant to be Shut Down
Sep 30, 2014  
The largest dry-cell battery manufacturer in the region of East Africa, Eveready East Africa Ltd. intends on shutting down its one and only factory in Kenya on the 1st of October 2014. A real estate business will be started in its place. According to the Managing Director of Eveready East Africa Ltd. the plan of shutting down the plant was initiated by the board members of this company...
Sale of Apples iPhones Remains Unaffected - Supported By Consumer Feedback
Sep 29, 2014  
iPhones have been reintroduced in the global market by Apple Inc. in about 22 countries. Consumer reports and feedback basically show that due to the presence of a problem-free backing and update, these handsets are sturdy and do not bend easily. It has been observed via stress tests conducted on iPhone 6 and 6 Plus, that it requires high force and pressure to cause damage to these...
New Malware Targets Pharma Servers
Sep 29, 2014  
The electronics and communication agency Beldon has reportedly spotted a new cyber threat to the pharmaceutical industry. Called Dragonfly, the malware specifically targets intellectual property of servers in the pharmaceutical industry with the purpose of stealing information. An initial report released by ipprolifesciences.com stated the malware was targeting the energy sector....
Child’s Success Depends on Father’s Education Level: Study
Sep 24, 2014  
A father’s level of education is the strongest attribute that can determine a child’s success in academics, according to a research conducted in Britain. It also says that there is a self-reinforcing cycle of lack of achievement and poverty that is handed down from parent to child. The report was released by the Office for National Statistics and states that children are...